Haisco Pharmaceutical Group (002653) Stock Overview
Researches, develops, manufactures, and sells pharmaceutical products in China. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 2/6 |
002653 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Haisco Pharmaceutical Group Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥44.35 |
| 52 Week High | CN¥48.89 |
| 52 Week Low | CN¥25.48 |
| Beta | -0.12 |
| 1 Month Change | -4.52% |
| 3 Month Change | -2.36% |
| 1 Year Change | 42.33% |
| 3 Year Change | 171.59% |
| 5 Year Change | 82.89% |
| Change since IPO | 529.57% |
Recent News & Updates
Recent updates
An Intrinsic Calculation For Haisco Pharmaceutical Group Co., Ltd. (SZSE:002653) Suggests It's 30% Undervalued
Mar 24
Is Haisco Pharmaceutical Group Co., Ltd. (SZSE:002653) Trading At A 38% Discount?
Dec 19Haisco Pharmaceutical Group Co., Ltd.'s (SZSE:002653) Shares May Have Run Too Fast Too Soon
Nov 19Haisco Pharmaceutical Group's (SZSE:002653) Promising Earnings May Rest On Soft Foundations
Aug 22With Haisco Pharmaceutical Group Co., Ltd. (SZSE:002653) It Looks Like You'll Get What You Pay For
Jul 25Shareholder Returns
| 002653 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -0.9% | 1.1% | 1.7% |
| 1Y | 42.3% | 25.1% | 24.6% |
Return vs Industry: 002653 exceeded the CN Pharmaceuticals industry which returned 25.1% over the past year.
Return vs Market: 002653 exceeded the CN Market which returned 24.6% over the past year.
Price Volatility
| 002653 volatility | |
|---|---|
| 002653 Average Weekly Movement | 7.2% |
| Pharmaceuticals Industry Average Movement | 4.9% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in CN Market | 8.6% |
| 10% least volatile stocks in CN Market | 2.8% |
Stable Share Price: 002653's share price has been volatile over the past 3 months compared to the CN market.
Volatility Over Time: 002653's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of CN stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 5,337 | Xiu Lian Fan | www.haisco.com |
Haisco Pharmaceutical Group Co., Ltd. researches, develops, manufactures, and sells pharmaceutical products in China. The company offers anesthetic analgesic, neuropsychiatric system, and digestive liver and parenteral nutrition medications; drugs for the endocrine and cardiovascular system; oncology-related drugs; andrology drugs; desonide and liprocaine cream; propofol medium/long chain fat emulsion and hydroxyethyl starch sodium chloride injection; sodium fusidicate ointment; lupatadine fumarate tablets; and caspofungin acetate and methylprednisolone sodium succinate for injection. It also develops Sisuning for sedation and anesthesia during surgery/procedure for non-endotracheal intubation, general anesthesia induction and maintenance, sedation in mechanical ventilation during intensive care, pediatric indications, and general anesthesia induction; Simenine for diabetic peripheral neuralgia, postherpetic neuralgia, and central nervous system analgesia; Beichangping for type 2 diabetes; Sysojing for postoperative analgesia of abdominal surgery, chronic kidney disease itching, orthopedic analgesia, and postoperative nausea and vomiting; HSK31858 for non-cystic fibrosis bronchiectasis, bronchial asthma, chronic obstructive pulmonary disease, and expectorant; HSK31679 for nonalcoholic steatohepatitis; HSK39297 for PHN of hemolytic disease and primary or secondary glomerular disease; HSK39775 and HSK42360 for advanced solid tumors; HSK39004 and HL231 for chronic obstructive pulmonary disease; HSK44459 for interstitial lung disease; HSK46575 for prostate cancer; and HSK41959 for advanced solid tumors.
Haisco Pharmaceutical Group Co., Ltd. Fundamentals Summary
| 002653 fundamental statistics | |
|---|---|
| Market cap | CN¥49.20b |
| Earnings (TTM) | CN¥350.11m |
| Revenue (TTM) | CN¥3.86b |
Is 002653 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 002653 income statement (TTM) | |
|---|---|
| Revenue | CN¥3.86b |
| Cost of Revenue | CN¥1.09b |
| Gross Profit | CN¥2.77b |
| Other Expenses | CN¥2.42b |
| Earnings | CN¥350.11m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
Aug 23, 2025
| Earnings per share (EPS) | 0.32 |
| Gross Margin | 71.72% |
| Net Profit Margin | 9.07% |
| Debt/Equity Ratio | 53.6% |
How did 002653 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/07/13 13:17 |
| End of Day Share Price | 2025/07/11 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Haisco Pharmaceutical Group Co., Ltd. is covered by 10 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Shanshan Li | China Merchants Securities Co. Ltd. |
| Chao Li | Citic Securities Co., Ltd. |
| Qianli Ma | Guosen Securities Co., Ltd. |